Dual MAPK/CDK Targeting in Melanoma: New Approaches, New Challenges [In the Spotlight]

Summary: Dual MAPK and CDK4/6 targeting is an emerging strategy in melanoma, but toxicity and acquired resistance are limitations. In this issue, two groups (Teh and colleagues and Romano and colleagues) show that therapeutic resistance mechanisms converge on the PI3K pathway, and inhibition of this pathway's mediators can overcome this resistance. Cancer Discov; 8(5); 532–3. ©2018 AACR.

See related article by Romano et al., p. 556.

See related article by Teh et al., p. 568.

from Cancer via ola Kala on Inoreader https://ift.tt/2JFPF7y
via IFTTT